Evaluation of Quality of Life in Ischemic Stroke Patients Treated with Tissue Plasminogen Activator

Document Type : Original Article(s)

Authors

1 Associate Professor, Department of Emergency Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Medical Student, Department of Emergency Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Assistant Professor, Department of Oral and Maxillo-facial Diseases, Dental Implants Research Center, Dental Research Institute, School of Dentistry, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Evaluation of Health-Related Quality of Life (HR-QoL) in Survivors of Acute Ischemic Stroke Treated with Tissue Plasminogen Activator (tPA) is the main objective of this study.
Methods: This cross-sectional study was performed to evaluate the HR-QoL of survivors of acute ischemic stroke who underwent thrombolytic treatment in Al-Zahra Hospital Isfahan in 2017. SS-QoL questionnaire was used to assess HR-QoL. Patients' hospital records were reviewed and demographic information and stroke were extracted. The relationship between the SS-QoL overall score and its sub-scores with contextual variables was analyzed.
Findings: A total of 59 patients were included in the study, of which (40.7%) 21 were female. The mean age of onset of stroke was 65.39 ± 11.85 years and the mean age of stroke and tPA was 0.46 ± 0.29 years. Blood pressure (49.2%) was the most common underlying disease. The majority of strokes in the left hemisphere (42.4%) were moderate (69.5%) and thrombotic (49.2%). The overall score of SS-QoL in (80.3%) of 49 patients was more than 147, indicating appropriate HR-QoL. There was no significant relationship between SS-QoL overall score with age, sex, type and, severity of stroke and time interval to tPA.
Conclusion: More than 80% of patients had a good quality of life. The underlying variables had no significant effect on patients' HR-QoL.

Highlights

Mehdi Nasr Isfahani: PubMed , Google Scholar

Mohammad Saadatnia: PubMed , Google Scholar

Fahimeh Pakravan: PubMed , Google Scholar

Keywords

Main Subjects

References

  1. Ovbiagele B, Nguyen-Huynh MN. Stroke epidemiology: advancing our understanding of disease mechanism and therapy. Neurotherapeutics 2011; 8(3): 319-29.
  2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 2015; 131(4): e29-322.
  3. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383(9913): 245-55.
  4. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011; 123(4): e18-209.
  5. Donnan GA, Baron JC, Ma H, Davis SM. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol 2009; 8(3): 261-9.
  6. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333(24): 1581-8.
  7. Lyden PD. In anticipation of international stroke trial-3 (IST-3). Stroke 2012; 43(6): 1691-4.
  8. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352(9136): 1245-51.
  9. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005; 36(7): 1432-8.
  10. Williams LS, Weinberger M, Harris LE, Biller J. Measuring quality of life in a way that is meaningful to stroke patients. Neurology 1999; 53(8): 1839-43.
  11. Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, et al, Technology Assessment Committee of the Society of Interventional Radiology. Trial design and reporting standards for intraarterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003; 34(8): e109-37.
  12. Pierot L, Gralla J, Cognard C, White P. Mechanical thrombectomy after IMS III, synthesis, and MR-RESCUE. American Journal of Neuroradiology. 2013 Sep 1;34(9):1671-3.
  13. Donkor ES, Owolabi MO, Bampoh PO, Amoo PK, Aspelund T, Gudnason V. Profile and health-related quality of life of Ghanaian stroke survivors. Clin
    Interv Aging 2014: 1701-8.
  14. Diard-Detoeuf C, Debiais S, Imbert M, Musikas A, Gaudron M, Laurent E, et al. Quality of life after off-label thrombolysis for ischemic stroke in elderly patients. Drugs Aging 2015; 32(11): 917-26.
  15. Palesch YY, Yeatts SD, Tomsick TA, Foster LD, Demchuk AM, Khatri P, et al. Twelve-month clinical and quality-of-life outcomes in the Interventional Management of Stroke III trial. Stroke 2015; 46(5): 1321-7.
  16. Lopez-Espuela F, Zamorano JD, Ramírez-Moreno JM, Jiménez-Caballero PE, Portilla-Cuenca JC, Lavado-García JM, et al. Determinants of quality of life in stroke survivors after 6 months, from a comprehensive stroke unit: a longitudinal study. Biol Res Nurs 2015; 17(5): 461-8.
  17. Mahmoodi M, Safari A, Vossoughi M, Golbon-Haghighi F, Kamali-Sarvestani M, Ghaem H, et al. Stroke specific quality of life questionnaire: Test of reliability and validity of the Persian version. Iran J Neurol 2015; 14(2): 94-100.
  18. Grabowska-Fudala B, Jaracz K, Górna K, Jaracz J, Kaźmierski R. Clinical recovery and health-related quality of life in ischaemic stroke survivors receiving thrombolytic treatment: a 1-year follow-up study. J Thromb Thrombolysis 2017; 43(1): 91-7.
  19. Schwab-Malek S, Vatankhah B, Bogdahn U, Horn M, Audebert HJ. Depressive symptoms and quality of life after thrombolysis in stroke: the TEMPiS study. J Neurol 2010; 257(11): 1848-54.
  20. de Weerd L, Luijckx GJ, Groenier KH, van der Meer K. Quality of life of elderly ischaemic stroke patients one year after thrombolytic therapy. A comparison between patients with and without thrombolytic therapy. BMC Neurol 2012; 12: 61.
  21. Chen X, Wang X, Delcourt C, Li J, Arima H, Hackett ML, et al. Ethnicity and other determinants of quality of functional outcome in acute ischemic stroke: the ENCHANTED trial. Stroke 2020; 51(2): 588-93.
  22. Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke: results from the Auckland Stroke Study, 1991–1992. Stroke 2000; 31(2): 440-7.
  23. Phan HT, Blizzard CL, Reeves MJ, Thrift AG, Cadilhac DA, Sturm J, et al. Sex differences in long-term quality of life among survivors after stroke in the INSTRUCT. Stroke 2019; 50(9): 2299-306.
  24. Deb-Chatterji M, Konnopka A, Flottmann F, Leischner H, Fiehler J, Gerloff C, et al. Patient-reported, health-related, quality of life after stroke thrombectomy in clinical practice. Neurology 2020; 95(12): e1724- e1732.
Journal of Isfahan Medical School
Volume 41, Issue 737
1st Week, December
November and December 2023
Pages 846-852

Files

History

  • Receive Date: 07 February 2023
  • Revise Date: 20 November 2023
  • Accept Date: 22 November 2023

Share

How to cite

Statistics